Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Relinqing Tablets is a Traditional Chinese Medicine (TCM) formulation developed and marketed by Zhejiang Kangde Pharmaceutical. It is prepared from the medicinal plant *Polygonum capitatum* Buch-Ham. ex D., a traditional Miao-nationality herb. The drug is approved by the Chinese Food and Drug Administration (NMPA) for the treatment of urinary system diseases, including urinary tract infections, pyelonephritis, cystitis, and urinary calculi. In TCM terms, it is characterized by its ability to clear heat, reduce fire, and promote diuresis, thereby addressing symptoms like frequent, urgent, and painful urination. The Relinqing series, which also includes granules and capsules, is recognized as a leading Chinese patent medicine for urinary tract conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Relinqing Tablets.